{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T12:22:18Z","timestamp":1769170938601,"version":"3.49.0"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","license":[{"start":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T00:00:00Z","timestamp":1583971200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>A granule formulation of baloxavir marboxil, a selective inhibitor of influenza cap-dependent endonuclease, was newly developed for children with difficulty swallowing tablets.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A multicenter open-label study was conducted during the 2017\u20132018 influenza season to assess the safety, pharmacokinetics and clinical\/virologic outcomes of single, oral, weight-based doses of baloxavir granules in Japanese children infected with influenza virus. The primary clinical endpoint was the time to illness alleviation of influenza.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>All 33 enrolled children completed the study and received baloxavir (1\u2009mg\/kg for 12 children weighing &lt;10\u2009kg, 10\u2009mg for 21 children weighing 10 to &lt;20\u2009kg). Detected viruses were influenza B (36.4%), A(H1N1)pdm09 (33.3%) and A(H3N2) (27.3%). Adverse events (AEs) were reported in 54.5% of children. No deaths, serious AEs or AEs leading to discontinuation were reported. The mean (SD) plasma concentrations of baloxavir acid at 24 hours post-dose were 72.8 (24.0) and 51.3 (19.3) ng\/mL in the 1-mg\/kg and 10-mg dose groups, respectively. The median time to illness alleviation (95% confidence interval) was 45.3 (28.5\u201364.1) hours. A &gt;4-log decrease in infectious viral titer occurred on day 2 and a temporary 2-log increase on day 4. Polymerase acidic protein\/I38T\/M-substituted viruses were detected in 5 children infected with influenza A, but none with influenza B.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Baloxavir granules and the weight-based dose regimen were considered to be well tolerated in children, with rapid influenza virus reduction and associated symptom alleviation. Evidence of baloxavir activity against influenza B was observed, but further data are required for confirmation.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000002748","type":"journal-article","created":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T04:05:03Z","timestamp":1590465903000},"page":"706-712","source":"Crossref","is-referenced-by-count":23,"title":["Baloxavir Marboxil 2% Granules in Japanese Children With Influenza"],"prefix":"10.1097","volume":"39","author":[{"given":"Takato","family":"Yokoyama","sequence":"first","affiliation":[{"name":"Yokoyama Children\u2019s Clinic, Kasuga, Fukuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Sakaguchi","sequence":"additional","affiliation":[{"name":"Biostatistics Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Ishibashi","sequence":"additional","affiliation":[{"name":"Project Management Department"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takao","family":"Shishido","sequence":"additional","affiliation":[{"name":"Drug Discovery & Disease Research Laboratory, Shionogi & Co., Ltd., Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro A.","family":"Piedra","sequence":"additional","affiliation":[{"name":"Department of Molecular Virology and Microbiology, and Pediatrics, Baylor College of Medicine, Houston, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chisako","family":"Sato","sequence":"additional","affiliation":[{"name":"Yokoyama Children\u2019s Clinic, Kasuga, Fukuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Tsuchiya","sequence":"additional","affiliation":[{"name":"Yokoyama Children\u2019s Clinic, Kasuga, Fukuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeki","family":"Uehara","sequence":"additional","affiliation":[{"name":"Project Management Department"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,3,12]]},"reference":[{"key":"R2-20230912","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciy866","article-title":"Clinical practice guidelines by the infectious diseases society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenzaa.","volume":"68","author":"Uyeki","year":"2019","journal-title":"Clin Infect Dis"},{"key":"R3-20230912","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1086\/505122","article-title":"Histopathologic and immunohistochemical features of fatal influenza virus infection in children during the 2003-2004 season.","volume":"43","author":"Guarner","year":"2006","journal-title":"Clin Infect Dis"},{"key":"R4-20230912","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1542\/peds.2008-1336","article-title":"Influenza-associated pediatric mortality in the United States: increase of Staphylococcus aureus coinfection.","volume":"122","author":"Finelli","year":"2008","journal-title":"Pediatrics"},{"key":"R5-20230912","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1086\/341407","article-title":"Encephalitis and encephalopathy associated with an influenza epidemic in Japan.","volume":"35","author":"Morishima","year":"2002","journal-title":"Clin Infect Dis"},{"key":"R6-20230912","doi-asserted-by":"crossref","first-page":"e014546","DOI":"10.1136\/bmjopen-2016-014546","article-title":"Factors associated with non-persistence to oral and inhaled antiviral therapies for seasonal influenza: a secondary analysis of a double-blind, multicentre, randomised clinical trial.","volume":"7","author":"Flicoteaux","year":"2017","journal-title":"BMJ Open"},{"key":"R7-20230912","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40780-017-0094-7","article-title":"Impact of the number of repeated inhalations and patient characteristics on the residual amount of inhaled laninamivir octanoate hydrate dry powder in pediatric patients with influenza.","volume":"3","author":"Murasaka","year":"2017","journal-title":"J Pharm Health Care Sci"},{"key":"R8-20230912","doi-asserted-by":"crossref","first-page":"9633","DOI":"10.1038\/s41598-018-27890-4","article-title":"Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil.","volume":"8","author":"Omoto","year":"2018","journal-title":"Sci Rep"},{"key":"R9-20230912","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.antiviral.2018.10.008","article-title":"In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit.","volume":"160","author":"Noshi","year":"2018","journal-title":"Antiviral Res"},{"key":"R10-20230912","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJMoa1716197","article-title":"Baloxavir marboxil for uncomplicated influenza in adults and adolescents.","volume":"379","author":"Hayden","year":"2018","journal-title":"N Engl J Med"},{"key":"R11-20230912","first-page":"ciz908","article-title":"Baloxavir marboxil in Japanese pediatric patients with influenza: safety and clinical and virologic outcomes.","volume":"pii","author":"Hirotsu","year":"2019","journal-title":"Clin Infect Dis"},{"key":"R12-20230912","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1016\/j.xphs.2019.04.010","article-title":"Population pharmacokinetics of baloxavir marboxil in Japanese pediatric influenza patients.","volume":"108","author":"Koshimichi","year":"2019","journal-title":"J Pharm Sci"},{"key":"R13-20230912","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/j.xphs.2018.12.005","article-title":"Population pharmacokinetic and exposure-response analyses of baloxavir marboxil in adults and adolescents including patients with influenza.","volume":"108","author":"Koshimichi","year":"2019","journal-title":"J Pharm Sci"},{"key":"R14-20230912","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1128\/AAC.01755-09","article-title":"Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection.","volume":"54","author":"Sugaya","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"R15-20230912","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1128\/AAC.00132-11","article-title":"Efficacy, safety, and pharmacokinetics of intravenous peramivir in children with 2009 pandemic H1N1 influenza A virus infection.","volume":"56","author":"Sugaya","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"R16-20230912","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/INF.0b013e31828ba08c","article-title":"Does respiratory virus coinfection increases the clinical severity of acute respiratory infection among children infected with respiratory syncytial virus?","volume":"32","author":"Harada","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"R17-20230912","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/00006454-200102000-00002","article-title":"Oral oseltamivir treatment of influenza in children.","volume":"20","author":"Whitley","year":"2001","journal-title":"Pediatr Infect Dis J"},{"key":"R18-20230912","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1086\/656408","article-title":"Early oseltamivir treatment of influenza in children 1-3 years of age: a randomized controlled trial.","volume":"51","author":"Heinonen","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R19-20230912","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S1473-3099(13)70267-6","article-title":"Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial.","volume":"14","author":"Fry","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"R20-20230912","article-title":"Baloxavir marboxil single-dose treatment in influenza-infected children: a randomized, double-blind, active controlled phase 3 safety and efficacy trial (miniSTONE-2).","author":"Baker","journal-title":"Pediatr Infect Dis J"},{"key":"R21-20230912","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/irv.12534","article-title":"Five years of monitoring for the emergence of oseltamivir resistance in patients with influenza A infections in the Influenza Resistance Information Study.","volume":"12","author":"Lina","year":"2018","journal-title":"Influenza Other Respir Viruses"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000002748","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T23:12:19Z","timestamp":1694560339000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000002748"}},"subtitle":["An Open-label Phase 3 Study"],"short-title":[],"issued":{"date-parts":[[2020,3,12]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000002748","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3,12]]}}}